Efficacy and safety of sialis in erectile dysfunction


Cite item

Full Text

Abstract

References

  1. McKinlay J. The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot. Res. 2000; 2 (suppl. 4): S6-Sll.
  2. Aytac L, Mckinlay J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Int. Br. J. Urol. 1999; 84: 50-56.
  3. Chew K., Earle C, Stuckey B. et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int. J. Impot. Res. 2000; 12 (1): 41-45.
  4. Meuleman E. J., Bonkers L. H., Robertson С et al. Erectile dysfunction: prevalence and effect on the quality of life Boxmeer study. Ned. Tijdschr. Geneesk. 2001; 145: 576-581.
  5. www.consort-statement.org
  6. European Association of Urology. Guidelines. 2000.
  7. Angulo J., Gadau M., Fernandez A. et al. IC351 enhances NOmediatedet relaxation of human arterial and trabecular penile amooth muscle. Eur. Urol. 2001; 39 (suppl. 5): abstr. 415.
  8. Giuliano F., Varfnese L. Tadalafil: a novel treatment for erectile dysfunction. Eur. Heart. J. Suppl. 2002; 4 (suppl. H): H24-H31.
  9. Kuan J. Brock G. Expert opinion. Invest. Drugs 2002; 11 (11): 1605-1613.
  10. Ballard S., Gingell C., Tang K. et al. Effects of sildenafil on the relaxation of human corpus cavernosum in vitro and on the activities of cyclic nucleotide phosphodiesterase izozymes. J. Urol. (Baltimore) 1998; 159: 2164-2171.
  11. Eardley I., Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int. J. Clin. Pract. 2002; 56 (4): 300-304.
  12. Corbin J., Francis S., Webb D. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002; 60: 4-11.
  13. Padma-Nathan H., Rosen R., Shabsigh R. et al. Tadalafil (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). Int. J. Impot. Res. 2001; 13 (suppl. 4): S33, abstr. 88. Data on file Lilly Icos LLC 2003
  14. Patterson В., Bedding A., Jewell H. et al. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int. J. Impot. Res. 2001; 13 (suppl. 5): S62, abstr. 16.
  15. Brock G., McMahon C., Chen K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. (Baltimore) 2002; 168 (4, pt 1): 1332-1336.
  16. Rosen R. C., Riley A., Wagner G. et al. The International Index of Erectile Function (IIEF): multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
  17. Conte H. R. Development and use of self-report techniques for assessing sexual function: a review and critique. Arch. Sex. Behav. 1983; 12: 555-576.
  18. Saenz De Tejada I., Anglin G., Knight J. R., Emmick J. T. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25 (12): 2159-2164.
  19. Hellstrom W. Tadalafil has no clinically relevant effect on semen characteristics. 2002. - poster presented at ESSIR.
  20. Kloner R., Mitchell M., Bedding A., Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J. Urol. (Baltimore) 2002; 167 (4): 176-177. abstr. 708.
  21. Kloner R., Watkins V., Costigan T. et al. Cardiovascular profile of tadalafil: a new PDE5 inhibitor. Ibid. 176, abstr. 707.
  22. Emmick J. Т., Stuewe S. R., Mitchell S.I. Owerview of cardiovascular effects of tadalafil. Eur. Heart J. Suppl. 2002; 4 (suppl. H): H32-H47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies